#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Obstacles and problems in global elimination of viral hepatitis C


Authors: Laura Krekulová 1,2;  Radkin Honzák 1,3
Authors‘ workplace: Remedis, s. r. o., Praha 1;  4. interní klinika 1. LF UK a VFN v Praze 2;  IKEM, Praha 3
Published in: Čas. Lék. čes. 2020; 159: 213-216
Category: Review Article

Overview

The global elimination of viral hepatitis C (HCV) infection according to WHO plan 2016 is conditioned by controlling the HCV epidemic among people who inject drug (PWID). This high-risk subpopulation has no interest in prevention, diagnostic or treatment of HCV infection. The problem is not only the lack of interest in changing their behaviour pattern, but also inability of health care professionals to conduct efficient assistance to PWID. The key to any successful intervention or treatment is to master the communication with problem patients. Providing efficient care of PWID with HCV is the most important step to successful HCV elimination.

Keywords:

viral hepatitis C – HCV infection – WHO plan of HCV elimination – people who inject drug (PWID) – interdisciplinary cooperation


Sources
  1. World Health Organization. Global Hepatitis Report, 2017. World Health Organization, Ženeva, 2017.
  2. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2: 161–176.
  3. Hajarizadeh B, Cunningham EB, Reid H et al. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2018; 3: 754–767.
  4. Grebely J, Larney S, Peacock A et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction 2019; 114: 150–166.
  5. Wiessing L, Ferri M, Grady B et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One 2014; 9: 1099–1109.
  6. World Health Organisation. Global health sector strategy on viral hepatitis 2016-2021: towards ending viral hepatitis. Dostupné na: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1
  7. Degenhardt L, Charlson F, Stanaway J et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis 2016; 16: 1385–1398.
  8. Degenhardt L, Peacock A, Colledge S et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health 2017; 5: e1192–e1207.
  9. Němeček V, Částková J, Fritz P et al. The 2001 serological survey in the Czech Republic – viral hepatitis. Cent Eur J Public Health 2003; 11 (suppl.): 54–61.
  10. Mravčík V, Chomynová P, Grohmannová K a kol. Výroční zpráva o stavu ve věcech drog pro Evropské monitorovací středisko pro drogy a drogové závislosti: Česká republika. Úřad vlády ČR, Praha, 2017.
  11. Zábranský T, Mravčík V, Korčišová B et al. Hepatitis C virus infection among injecting drug users in the Czech Republic – prevalence and associated factors. Eur Addict Res 2006; 12: 151–160.
  12. Mravčík V, Chomynová P, Grohmannová K a kol. Výroční zpráva o stavu ve věcech drog v České republice v roce 2018. Úřad vlády ČR, Praha, 2019.
  13. Mravčík V (ed.). Výskyt VHC u injekčních uživatelů drog: výsledky studie prováděné mezi klienty nízkoprahových zařízení v letech 2002–2005. Úřad vlády ČR, Praha, 2009.
  14. Eliminace virové hepatitidy typu C mezi uživateli drog v České republice: východiska a akční plán na období 2019–2021. Národní monitorovací středisko pro drogy a závislosti, Praha, 2019.
  15. Dennistron MM, Klevens RM, McQuillan GM et al. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatol 2012; 55: 1652–1661.
  16. Sharma SA, Feld JJ. Acute hepatitis C: management in the rapidly evolving world of HCV. Curr Gastroenterol Rep 2014; 16: 371.
  17. Tucker JD, Meyers K, Best J et al. The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing. BMC Infect Dis 2017; 17: 701.
  18. Mitchell O, Gurakar A. Management of hepatitis C post-liver transplantation: a comprehensive review. JCTH 2015; 3: 140–148.
  19. Eliminace virové hepatitidy typu C mezi uživateli drog v České republice: východiska a akční plán na období 2019–2021. Národní monitorovací středisko pro drogy a závislosti, Praha, 2019.
  20. Larney S, Peacock A, Leung J et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health 2017; 5: e1208–e1220.
  21. Hickman M, De Angelis D, Vickerman P et al. Hepatitis C virus treatment as prevention in people who inject drugs. Curr Opin Infect Dis 2015; 28: 576–582.
  22. Midgard H, Bramness JG, Skurtveit S et al. Hepatitis C treatment uptake among patients who have received opioid substitution treatment: a population-based study. PLoS One 2016; 11: e0166451.
  23. Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 2010; 376: 355–366.
  24. Christensen S, Buggish P, Mauss S et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice? Addiction 2018; 113: 868–882.
  25. Dore GJ, Grebely J, Altice F et al. Hepatitis C Virus (HCV) reinfection and injecting risk behavior following elbasvir (EBR)/Grazoprevir (GZR) treatment in participants on opiate agonist therapy (OAT): Co-STAR Part B. Hepatol 2017; 66, 112A.
  26. Page K, Morris MD, Hahn JA et al. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis 2013; 57: S32–S38.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist

Article was published in

Journal of Czech Physicians


Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#